Scientific R&D

SBK002 is a Class 1 innovative drug indicated for the secondary prevention of atherothrombotic events, such as myocardial infarction, ischemic stroke, or peripheral arterial disease in high-risk patients. It demonstrates enhanced safety, reduced hepatic and renal burden, and minimized drug-drug interactions.

China: SBK001 NDA to CDE 2025

USA: SBK001 FDA IND cleared (Feb 1, 2025) 

EU: SBK001 EMA IND filing expected late 2025 

SBK001 is a Class 1 innovative drug featuring a novel molecular compound structure, primarily indicated for acute lung injury (ALI) and expectorant therapy. It offers improved clinical safety and superior efficacy, providing more therapeutic options for patients with respiratory diseases.

China: Phase II (expectorant) initiated; Phase I (lung injury) completed
USA/EU: SBK001 under FDA/EMA review

SBK007 is a Class 1 innovative drug with a novel molecular compound structure. Currently, it is primarily developed for two indications: the treatment of acute urticaria in adults and the relief of symptoms associated with allergic rhinitis (seasonal and perennial). As a next-generation (3rd-gen) antihistamine, it delivers novel mechanisms and high efficacy in allergy management.

China: SBK007 is expected to initiate Phase II clinical trials for the allergic rhinitis indication in Q1 2026, while Phase I clinical trials for the acute urticaria indication have already been completed
US/EU: IND submission to FDA/EMA by EOY 2025

SBK009 can effectively inhibit ADP-induced platelet aggregation with favorable safety and tolerability, making it a promising new option for antiplatelet therapy.

China: IND approval in Q3 2025
US/EU: Global GMP clinical samples (Phase I/II) – US/EU/China compliant 

SBK013 is a Class 1 innovative drug with a novel compound structure, intended for the prevention of arterial and venous thromboembolic diseases. It aims to compete with existing anticoagulants by addressing the shortcomings of current treatment options and providing a more effective solution for the prevention and treatment of thrombotic diseases.

China: NMPA clinical trial approval (Mar 6, 2025)
US/EU: Global GMP clinical samples (Phase I/II) – US/EU/China compliant 

11.SBK010 is a Class 2 innovative drug with improved formulation, indicated for ischemic stroke. It demonstrates excellent therapeutic efficacy while significantly improving patient compliance.

In September 2024, NDA submitted and accepted by NMPA in Sep 2024

SBK011 is a diagnostic reagent specifically designed for oral glucose tolerance tests (OGTT), set to fill the domestic commercialization gap in diabetes screening. It elevates diagnostic standardization and convenience.

SBK012 is a Class 2 innovative drug with improved formulation, indicated for acute ischemic stroke. It has successfully overcome the limitations of existing medications, completed clinical trials with favorable data across all evaluation metrics.

The New Drug Application (NDA) is expected to be submitted in 2025.

SHLQ Syrup is an approved Class 2 chemical new drug (GYZZ H20240034) indicated for sedation and hypnosis in children prior to surgical examinations or procedures. As China's first commercially available pediatric-specific SHLQ Syrup formulation, it significantly improves medication safety and compliance in children.

SHLQ Syrup included in NRDL on Nov 28, 2024